{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:59:04Z","timestamp":1790114344225,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100003399","name":"Science and technology commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["14401970900"],"award-info":[{"award-number":["14401970900"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13063-017-2140-z","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T08:09:55Z","timestamp":1503389395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Wei","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-1512","authenticated-orcid":false,"given":"Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuenong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,22]]},"reference":[{"key":"2140_CR1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","volume":"32","author":"EA Lefrak","year":"1973","unstructured":"Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302\u201314.","journal-title":"Cancer"},{"key":"2140_CR2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687\u2013717.","journal-title":"Lancet"},{"key":"2140_CR3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Hoff Von","year":"1979","unstructured":"Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710\u20137.","journal-title":"Ann Intern Med"},{"key":"2140_CR4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K","volume":"20","author":"C Tan","year":"1967","unstructured":"Tan C, Tasaka H, Yu KP, et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967;20:333\u201353.","journal-title":"Cancer"},{"issue":"9","key":"2140_CR5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","volume":"58","author":"Z Acar","year":"2011","unstructured":"Acar Z, Kale A, Turgut M, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58(9):988\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"2140_CR6","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","volume":"48","author":"N Kalay","year":"2006","unstructured":"Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2140_CR7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.phrs.2009.05.007","volume":"60","author":"MA Ibrahim","year":"2009","unstructured":"Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res. 2009;60(5):373\u201381.","journal-title":"Pharmacol Res"},{"issue":"3","key":"2140_CR8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2007.12.010","volume":"44","author":"F Nigris de","year":"2008","unstructured":"de Nigris F, Rienzo M, Schiano C, Fiorito C, Casamassimi A, Napoli C. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. Eur J Cancer. 2008;44(3):334\u201340.","journal-title":"Eur J Cancer"},{"key":"2140_CR9","doi-asserted-by":"crossref","unstructured":"Iarussi D, Auricchio U, Agretto A, Murano A, GiulianoM, Casale F, et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med. 1994;15(Suppl 3):207-12.","DOI":"10.1016\/0098-2997(94)90030-2"},{"key":"2140_CR10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/bmj.288.6413.283-a","volume":"288","author":"JA Whittaker","year":"1984","unstructured":"Whittaker JA, Al-Ismail SAD. Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia. Br Med J. 1984;288:283\u20134.","journal-title":"Br Med J"},{"issue":"2","key":"2140_CR11","first-page":"CD003917","volume":"6","author":"EV Dalen","year":"2011","unstructured":"Dalen EV, Kremer L. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;6(2):CD003917.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"2140_CR12","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938\u201345.","journal-title":"J Am Coll Cardiol"},{"key":"2140_CR13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","volume":"25","author":"CK Tebbi","year":"2007","unstructured":"Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin\u2019s disease. J Clin Oncol. 2007;25:493\u2013500.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2140_CR14","first-page":"460","volume":"43","author":"JH Doroshow","year":"1983","unstructured":"Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 1983;43(2):460\u201372.","journal-title":"Cancer Res"},{"key":"2140_CR15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00000421-198212000-00015","volume":"5","author":"AR Dresdale","year":"1982","unstructured":"Dresdale AR, Barr LH, Bonow RO, et al. Prospective randomized study of the role of N-acetylcysteine in reversing doxorubicin-induced cardiomyopathy. Am J Clin Oncol. 1982;5:657\u201363.","journal-title":"Am J Clin Oncol"},{"key":"2140_CR16","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.freeradbiomed.2003.08.005","volume":"35","author":"BB Hasinoff","year":"2003","unstructured":"Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med. 2003;35:1469\u201379.","journal-title":"Free Radic Biol Med"},{"key":"2140_CR17","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.phytochem.2004.08.030","volume":"65","author":"L Ji Young","year":"2004","unstructured":"Ji Young L, Jae Wook Y, Cheong Tae K, et al. Antioxidant activity of phenylpropanoid-esters isolated and identified from Platycodon grandiflorum A.DC. Phytochemistry. 2004;65:3033.","journal-title":"Phytochemistry"},{"issue":"12","key":"2140_CR18","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1016\/j.fct.2012.05.022","volume":"50","author":"T-W Kim","year":"2012","unstructured":"Kim T-W, Song I-B, Lee H-K, et al. Platycodin D, a triterpenoid sapoinin from Platycodon grandiflorum ameliorates cisplatin-induced nephrotoxicity in mice. Food Chem Toxicol. 2012;50(12):4254\u20139.","journal-title":"Food Chem Toxicol"},{"issue":"6","key":"2140_CR19","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1096\/fj.03-0724rev","volume":"18","author":"S Fogli","year":"2004","unstructured":"Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB. 2004;18(6):664\u201375.","journal-title":"FASEB"},{"issue":"1-2","key":"2140_CR20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11010-005-9072-8","volume":"285","author":"Y Cigremis","year":"2006","unstructured":"Cigremis Y, Parlakpinar H, Polat A, et al. Beneficial role of aminoguanidine on acute cardiomyopathy related to doxorubicin-treatment. Mol Cell Biochem. 2006;285(1-2):149\u201354.","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"2140_CR21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/jmf.2006.9.169","volume":"9","author":"MH Jang","year":"2006","unstructured":"Jang MH, Kim CJ, Kim EH, et al. Effects of Platycodon grandiflorum on lipopolysaccharide-stimulated production of prostaglandin E2, nitric oxide, and interleukin-8 in mouse microglial BV2 cells. J Med Food. 2006;9(2):169\u201374.","journal-title":"J Med Food"},{"issue":"11","key":"2140_CR22","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/S1567-5769(01)00124-2","volume":"1","author":"SB Han","year":"2001","unstructured":"Han SB, Park SH, Lee KH, et al. Polysaccharide isolated from the radix of Platycodon grandiflorum selectively activates B cells and macrophages but not T cells. Int Immunopharmacol. 2001;1(11):1969\u201378.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"2140_CR23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10549-016-3781-4","volume":"156","author":"G Murtagh","year":"2016","unstructured":"Murtagh G, Lyons T, O\u2019Connell E, et al. Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up. Breast Cancer Res Treat. 2016;156(3):501\u20136.","journal-title":"Breast Cancer Res Treat"},{"key":"2140_CR24","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). (v4.03: June 14, 2010). 2010. \nhttp:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm\n\n. Accessed 22 Jan 2016."},{"key":"2140_CR25","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jclinepi.2005.12.020","volume":"59","author":"JJ Gagnier","year":"2006","unstructured":"Gagnier JJ, Boon H, Rochon P, CONSORT Group, et al. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol. 2006;59:1134\u201349.","journal-title":"J Clin Epidemiol"},{"key":"2140_CR26","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-017-2140-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T08:10:19Z","timestamp":1503389419000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-017-2140-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,22]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2140"],"URL":"https:\/\/doi.org\/10.1186\/s13063-017-2140-z","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,22]]},"article-number":"386"}}